Skip to main content

Table 2 Toxicity and supportive care - incidence of severe toxicity among treated patients.

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

 

Group A (CP)

N= 89

Group B (CLD)

N= 84

 

Grade 1

Grade 2

Grade 3

Grade 4

Grade 1

Grade 2

Grade 3

Grade 4

Neutropenia

14 (16)

20 (22)

18 (20)

9 (10)

13 (15)

20 (24)

23 (27)

7 (8)

Anaemia

29 (33)

0 (0)

3 (3)

0 (0)

27 (32)

23 (27)

7 (8)

1 (1)

Leucopenia

24 (27)

23 (26)

5 (6)

1 (1)

25 (30)

30

4 (5)

1 (1)

Thrombocytopenia†

1 (1)

6 (7)

2 (2)

0 (0)

4 (5)

7 (8)

9 (10)

1 (1)

Stomatitis

 

1 (1)

 

0 (0)

7 (8)

5 (6)

3 (3)

0 (0)

Nausea/vomiting

18 (20)

10 (11)

1 (1)

0 (0)

16 (19)

12 (14)

4 (5)

0 (0)

Diarrhoea

5 (6)

1 (1)

1 (1)

0 (0)

5 (6)

1 (1)

0 (0)

0 (0)

Infection

1 (1)

3 (3)

 

0 (0)

3 (4)

1 81)

1 (1)

1 (1)

Neurotoxicity‡

24 (27)

27 (30)

5 (6)

1 (1)

19 (12)

1 (1)

0 (0)

0 (0)

Alopecia‡

1 (1)

56 (63)

18 (20)

0 (0)

12 (14)

5 (6)

4 (5)

0 (0)

Allergy

18 (20)

9 (10)

1 (1)

0 (0)

4 (5)

2 (2)

1 (1)

0 (0)

Skin

6 (7)

2 (2)

0 (0)

0 (0)

9 (11)

12 (14)

1 (1)

0 (0)

Hand and foot

0 (0)

0 (0)

0 (0)

0 (0)

2 (2)

8 (10)

0 (0)

0 (0)

Fatigue

12 (13)

6 (7)

0 (0)

0 (0)

8 (10)

6 (7)

0 (0)

0 (0)

Fever

 

5 (6)

0 (0)

0 (0)

2 (2)

4 (5)

0 (0)

0 (0)

Anorexia

4 (4)

2 (2)

0 (0)

0 (0)

5 (6)

 

0 (0)

0 (0)

Cardiac

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (1)

0 (0)

0 (0)

Arthralgias/myalgias

18 (20)

8 (9)

0 (0)

0 (0)

6 (7)

0 (0)

0 (0)

0 (0)

  1. †Rate of severe thrombocytopenia is higher among patients treated with CLD (group B) (11% versus 2%, p = 0.016)
  2. ‡Rates of severe neurotoxicity and alopecia are higher among patients treated in group A (CP; 7% versus 0%, P = 0.029 and 20% versus 5%, P = 0.003)